Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations



Status:Recruiting
Conditions:Cancer, Cancer, Thyroid Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:8/25/2018
Start Date:March 2015
End Date:August 2019
Contact:Kamn Lacroix
Email:medicalaffairs@kuraoncology.com
Phone:617-588-3760

Use our guide to learn which trials are right for you!

An Open Label Phase II Study of Tipifarnib in Advanced Non-Hematological Malignancies With HRAS Mutations

Phase II study to investigate the antitumor activity in terms of ORR of tipifarnib in
subjects with advanced tumors that carry HRAS mutations and for whom there is no standard
curative therapy available.

This Phase II study will investigate the antitumor activity in terms of ORR of tipifarnib in
subjects with locally advanced, unresectable or metastatic, relapsed and/or refractory tumors
that carry HRAS mutations and for whom there is no curative therapy available. Subject with
information available on tumor HRAS status previously generated are eligible. All subjects
must consent to provide at least 10 tumor slides from a prior diagnostic biopsy for a
retrospective testing of RAS gene status at a central facility.

Subjects will be enrolled into two nonrandomized cohorts:

- Cohort 1: Malignant thyroid tumors with HRAS mutations.

- Cohort 2: Squamous Head and Neck Cancer with HRAS mutations.

Inclusion Criteria:

- histologically or cytologically confirmed diagnosis of thyroid cancer (cohort 1) or
squamous head and neck cancer (cohort 2) for which there is no curative therapy
available.

- tumor that carries a missense HRAS mutation

- Subject consents to provide at least 10 unstained tumor slides for retrospective
testing of HRAS gene tumor status

- Subject has measurable disease according to RECIST v1.1 and has relapsed or is
refractory to prior therapy.

- At least 2 weeks since the last systemic therapy or radiotherapy regimen prior to
enrolment

- ECOG PS 0 or 1

- Acceptable liver function

- Acceptable renal function

- Acceptable hematologic status

Exclusion Criteria:

- Prior treatment with an FTase inhibitor

- History of relevant coronary heart disease or myocardial infarction within last 3
years, NYHA Grade III or greater congestive heart failure, cerebro-vascular attack
within the prior year, or serious cardiac arrhythmia requiring medication except
atrial fibrillation.

- Known uncontrolled brain, leptomeningeal or epidural metastases (unless treated and
well controlled for at least 4 weeks prior to Cycle 1 Day 1). Controlled brain
metastases that require continuous high dose corticosteroid use within 4 weeks of Day
1.

- Non-tolerable > Grade 2 neuropathy or evidence of unstable neurological symptoms
within 4 weeks first dose

- Major surgery, other than diagnostic surgery, within 4 weeks prior to first dose,
without complete recovery.

- Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic
therapy. Known infection with HIV, or an active infection with hepatitis B or
hepatitis C
We found this trial at
9
sites
1275 York Ave
New York, New York 10021
(212) 639-2000
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
?
mi
from
New York, NY
Click here to add this to my saved trials
Los Angeles, California 90095
310-825-4321
University of California at Los Angeles The University of California, Los Angeles (UCLA) is an...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
1500 East Medical Center Drive
Ann Arbor, Michigan 48109
800-865-1125
University of Michigan Comprehensive Cancer Center The U-M Comprehensive Cancer Center's mission is the conquest...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
?
mi
from
Antwerp,
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
1515 Holcombe Blvd
Houston, Texas 77030
 713-792-2121
University of Texas M.D. Anderson Cancer Center The mission of The University of Texas MD...
?
mi
from
Houston, TX
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19111
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19104
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Rochester, Minnesota 55905
?
mi
from
Rochester, MN
Click here to add this to my saved trials